|
Supplemental Disclosures of Cash Flow Information and Noncash Investing and Financing Activities
|
12 Months Ended |
|---|---|
|
Jun. 30, 2014
|
|
| Supplemental Disclosures of Cash Flow Information and Noncash Investing and Financing Activities |
M. Supplemental Disclosures of Cash Flow Information and Noncash Investing and Financing Activities: In fiscal 2014, the Company acquired PrimeGene for approximately $18.7 million. Approximately $6.0 million was paid at closing with approximately $12.7 million payable over fiscal years 2015 through 2017. In fiscal 2014, 2013 and 2012, the Company paid cash for income taxes of $55.2 million, $51.6 million and $58.7 million, respectively. In fiscal 2014, stock options for 1,077 shares of common stock were exercised by the surrender of 733 shares of common stock at fair market value of $56,000.
During fiscal 2012, the Company’s cost basis investment in CCXI was converted to an available-for-sale investment carried at fair value |
| X | ||||||||||
|
- Definition
The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|